Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

▪ Introduction. The phase 3 randomized, placebo-controlled trials of the SYK inhibitor fostamatinib in adult patients with ITP were followed by an open-label extension (OLE) study to examine durability of response to fostamatinib and to allow patients in the placebo group in the phase 3 trials to cr...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.736-736
Main Authors: Duliege, Anne-Marie, Arnold, Donald M., Boccia, Ralph, Boxer, Michael, Cooper, Nichola, Hill, Quentin A, Liles, Darla K, Sholzberg, Michelle, Zayed, Hany, Tong, Sandra, Bussel, James B.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:▪ Introduction. The phase 3 randomized, placebo-controlled trials of the SYK inhibitor fostamatinib in adult patients with ITP were followed by an open-label extension (OLE) study to examine durability of response to fostamatinib and to allow patients in the placebo group in the phase 3 trials to crossover to fostamatinib. This abstract provides an additional year of data from the OLE study in patients with up to 3 years of fostamatinib treatment. Methods. Patients were adults with persistent or chronic ITP who had failed ≥1 prior therapy and had ≥3 platelet counts below 30,000/μL at screening. Patients initiated fostamatinib treatment at 100mg BID PO and increased to 150 mg BID based on tolerability and if platelets were
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-110482